临床试验/NCT00376064

NCT00376064已完成4 期

A Multicenter, Single Arm, Proof of Concept Study to Investigate the Efficacy of an 8 Month Combination Therapy of Octreotide and Cabergoline in Acromegalic Patients Only Partially Responsive to Somatostatin Analog Monotherapy

Novartis Pharmaceuticals1 个研究点分布在 1 个国家目标入组 20 人开始时间: 2006年3月最近更新: 2017年3月6日

适应症

干预措施

试验速览

阶段: 4 期
状态: 已完成
发起方: Novartis Pharmaceuticals
入组人数: 20
试验地点: 1
主要终点: Biochemical control (% of patients) as measured by GH- and IGF-1-values (baseline, EOS)

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This study will investigate the efficacy of a combination treatment with octreotide acetate and cabergoline in acromegalic patients that are only partially responsive to a somatostatin analog monotherapy

研究设计

研究类型: Interventional
分配方式: Na
干预模型: Single Group
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

未提供

排除标准

未提供

研究组 & 干预措施

SMS995 + Carbegolin, Somavert + SMS995

Experimental

干预措施: Octreotide acetate and cabergoline/Octrotide and Somavert (Drug)

结局指标

主要结局

Biochemical control (% of patients) as measured by GH- and IGF-1-values (baseline, EOS)

时间窗: 8 months

次要结局

Biochemical control (mean, normalization) as measured by GH- and/or IGF-1-values(8 months)
Control clinical of symptoms of acromegaly(8 months)
Quality of Life assessment(8 months)
Safety and tolerability as assessed by frequency of AEs(8 months)
Effect of tumor size(8 months)

研究者

发起方

Novartis Pharmaceuticals

申办方类型

Industry

责任方

Sponsor

研究点 (1)

Loading locations...

相似试验

尚未招募

2 期

Preoperative Tislelizumab -Cetuximab - Chemotherapy Followed by Salvage Surgery and Adjuvant Tislelizumab -Cetuximab for Resectable, Locally Recurrent Oral and Oropharyngeal Squamous Cell CarcinomaOral Squamous Cell Carcinoma (OSCC)Oropharyngeal Squamous Cell Carcinoma (SCC)Resectable Oral and Oropharyngeal Squamous Cell CarcinomaRecurrent Oral and Oropharyngeal Squamous Cell Carcinoma

NCT06728618Shanghai Zhongshan Hospital28

已完成

不适用

Treatment of Pediculosis (Head Lice) in SenegalPediculoses

NCT03578679Institut de Recherche pour le Developpement450

已完成

4 期

Utilization of Narrow Band Ultraviolet B (UVB) Light Therapy and Etanercept for the Treatment of PsoriasisPsoriasis

NCT00110981Amgen86

已完成

2 期

Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal CancerBRAF V600E-mutant Metastatic Colorectal Cancer

NCT03693170Pierre Fabre Medicament95

招募中

3 期

Clinical Study of Combination Therapy With Ectiecinib, Pemetrexed and Platinum in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutations.Non-squamous Non-small Cell Lung Cancer

NCT03992885Tianjin Medical University Cancer Institute and Hospital70